Objective: Internet-delivered interventions may alleviate distress in cancer survivors with limited access to psychological face-to-face treatment. In collaboration with a group of cancer survivors, we developed and tested the efficacy of a therapistassisted internet-delivered mindfulness-based cognitive therapy (iMBCT) program for anxiety and depression in cancer survivors.
quality of life, poorer daily function, and-possibly-poorer cancer prognosis. 8, 9 Meta-analyses have shown mindfulness-based interventions (MBIs) to be efficacious for anxiety and depression with effect sizes (Hedges's g) up to 0.97 and 0.95 in patients with mood disorders 10 and 0.39 and 0.44 with cancer patients and survivors. 11 Despite documented efficacy, challenges remain to make MBIs available to patients in need because of limited number of trained therapists, costs, and restricted mobility and time constraints among cancer patients and survivors. [12] [13] [14] [15] Delivering interventions over the internet is an increasingly popular approach to overcome these challenges. A systematic review of eHealth interventions aimed at breast cancer patients and survivors supports the general feasibility and acceptability of internet-delivered interventions within this group, 16 and two previous studies of internet-delivered MBIs for psychological distress in cancer patients show promising results. 17, 18 One study of cancer patients participating in an online "Mindfulness-Based Cancer Recovery program" found an effect at post intervention on mood disturbance (d = 0.44) when compared with a wait-list control. 17 The second study explored mindfulness-based cognitive therapy (MBCT) for psychological distress in cancer patients and found relatively comparable post-intervention effects of internet-delivered (d = 0.71) and face-to-face-delivered MBCT (d = 0.45) compared with care-as-usual (CAU). 18 However, in both studies, long-term effects went uninvestigated and participants were recruited through self-referral, possibly introducing self-selection bias. Offering the intervention to patients identified through a systematic screening for distress during follow-up will add knowledge about the need for intervention and acceptability of internet delivery of such interventions.
Our aim was therefore to evaluate the efficacy of internet-delivered MBCT (iMBCT) offered as part of routine follow-up care to breast and prostate cancer survivors experiencing symptoms of anxiety and depression. Breast and prostate cancer were chosen as they are prevalent cancer types with high long-term survival rates. 19 We chose iMBCT as our group has previously found MBCT to be well-accepted and efficacious for treating persistent pain in breast cancer survivors. 20, 21 We compared iMBCT with waitlist CAU controls at post intervention and 6 months follow-up.
| METHODS

| Participants
A total of 150 breast and prostate cancer survivors were randomized to iMBCT (70%) or wait-list control (30%). Inclusion criteria were as follows: scoring greater than or equal to 3 when screened for symptoms of anxiety or depression on a 0-to 10-point numeric rating scale, more than or equal to 3 months and less than or equal to 5 years after completed primary treatment for primary breast or prostate cancer, age 18 years and older, ability to understand and read Danish, internet access, and mobile phone ownership. Exclusion criteria are as follows: cancer recurrence or active cancer treatment (except adjuvant endocrine treatment), insufficient IT skills (self-reported), and severe mental illness. The study was approved by the regional Science Ethics Committee (registration no: 1-10-72- ) and registered at ClinicalTrials.gov (NCT03100981).
| Sample size and randomization
The study was designed to include 155 participants. Randomization was conducted in blocks of 10, with seven blocks allocated to intervention and three to control. The unbalanced allocation aimed at increasing power for subsequent mediation analyses. On the basis of previous reports, we expected an uneven attrition rate of 25% in the intervention group and 15% in the control group, 22 leading to a final 80 and 41 participants in intervention and control, respectively. This would allow the detection of a statistical significant (P < .05) Time × Group interaction corresponding to an effect size (Hedge's g) of 0.60 with a statistical power of 83%. While larger than previously found for cancer patients and survivors, 11 the effect size is more conservative than those found for face-to-face MBIs with patients screened for mood disorders. 10 Because of resource and time constraints, recruitment was terminated after inclusion of 150 participants. Expecting an uneven number of eligible breast and prostate cancer survivors, computerized randomization was stratified according to cancer type. 23 The allocation sequence was generated by the primary investigator. Research assistants handling recruitment were unaware of group allocation until after the participant was included.
| Procedure
Participants were recruited between February 24, 2016 and August Wait-list controls received auto generated emails asking them to complete online questionnaires at times T2, T3, and T4. If questionnaires were not completed within 1 week, participants received up to three reminder emails. If participants did not respond to reminders, they received a telephone call from a research assistant. The reminder procedures were identical for the intervention and control group. After completing the T4 follow-up questionnaire, controls were offered iMBCT.
| Measures
| Screening
Eligible participants were screened for symptoms of depression and anxiety. Because routine care only allowed a brief screening procedure, a short two-item measure was used. Patients indicated on 11-point numerical rating scales (0 = not at all, 10 = very much) "Within the past week, how depressed and sad have you been?" and "Within the past week, how worried and anxious have you been?". The 3-point cut-off was based on our experiences with similar recruitment procedures. 21
| Participant characteristics
At T1, participants provided sociodemographic and clinical information on gender, date of birth, marital status, educational level, occupation, cancer type, time of diagnosis, and comorbidities. 29 
| Outcomes
The primary outcomes of anxiety and depression were assessed at T1, T2, T3, and T4 with the state subscale of the State-Trait Anxiety Inventory Y-Form (STAI-Y) 30 
and the Beck Depression Inventory
(BDI-II). 31 Internal consistencies (Cronbach's α) in the present sample were .94 and .85, respectively. Secondary outcomes included perceived stress measured at T1, T2, T3, and T4 with the Perceived Stress Scale (PSS-10) 32 ; well-being assessed at T1, T3, and T4 with the World Health Organization Well-Being Index (WHO-5) 33 ; and sleep disturbance measured at T1, T3, and T4 with the Insomnia Severity Index (ISI). 34 Internal consistencies in the present sample ranged from 0.85 to 0.87. Therapist time spent was recorded for each module and participant adherence to the intervention was assessed as total login times for the intervention platform and training website and the number of completed modules. A module was considered completed if the participant had returned a completed "tasks of the week" working sheet to the therapist. Additional variables, not reported on in the present paper, included measures of mindfulness, self-compassion, weekly distress, and therapeutic alliance. 
| Statistical methods
| RESULTS
| Participant characteristics
A total of 1282 cancer survivors were screened to obtain the final sample of 150 participants (Figure 1 ). Of these, 137 had been treated for breast cancer (mean age 54.55) and 13 for prostate cancer (mean age = 64.94). The screened patients (n = 1282) had an average score of 1.64 (SD = 2.39) on the depression screening item and 1.85 (SD = 2.55) on the anxiety screening item. Among the included participants, 21 (14.0%) scored greater than or equal to 3 on the anxiety item only, 10 (6.7%) scored greater than or equal to 3 on the depression item only, and 119 (79.3%) scored greater than or equal to 3 on both items. The mean scores of the included participants were 5.5
(SD = 2.1) for anxiety and 4.9 (SD = 2.2) for depression. No baseline differences between the intervention and control groups were found for any sociodemographic, clinical, or outcome variables (Table S3 ).
Participants treated for prostate cancer were significantly older, was associated with older age (P = .025) and being a woman/breast cancer survivor (P = .028). When comparing adherent (more than four completed modules) and non-adherent participants (less than or equal to four completed modules), no statistically significant differences were found for any of the participant characteristics assessed. Table S4 ). Model-fit analyses revealed that for anxiety linear and loglinear models showed comparable fits, whereas a log-linear model provided the best fit of the data for depression ( Figure S5 ). (Table 1 ).
| Primary outcomes
| Secondary outcomes
| Treatment adherence
Of the 104 participants randomized to intervention, 82 (79%) started iMBCT. Participants completed an average of 5.7 out of eight modules, with 46 (56%) completing all eight modules. The reported reasons for not starting or discontinuing iMBCT during the first 4 weeks (n = 51, 49.0%) were lack of motivation (n = 30, 28.8%), insufficient IT skills (n = 13, 12.5%), and cancer relapse or other physical problems (n = 3, 2.9%). Reasons are unknown for four participants (3.8%). Reasons for discontinuing treatment later than module four (n = 7, 6.7%) were lack of motivation (n = 6, 5.8%) and cancer relapse or other physical problems (n = 1, 1.0%). Login data showed that participants spent on average 39 hours and 15 minutes using the program, corresponding 
| DISCUSSION
The present study adds to the few available studies of effects of internet-delivered MBIs in cancer survivors 17, 18 and is the first to evaluate longer-term effects. The primary outcomes of anxiety and depression were improved immediately after the intervention with betweengroup effects largely maintained at the 6-month follow-up for anxiety, but not depression. Model fit analyses showed that the depression data fitted a log-linear curve, suggesting that the improvement in the intervention group occurred in the beginning of the study period and was maintained over time. However, as controls also experienced improvement over time, the between-group difference diminished at follow-up. Significant between-group effects were found for wellbeing at the 6-month follow-up assessment (d = 0.48). No effects were found for any of the remaining secondary outcomes (stress and insomnia) at any time point.
The effect on symptoms of anxiety remained statistically significant in the sensitivity analysis, suggesting that iMBCT may have a robust, durable effect on anxiety symptoms in breast and prostate cancer survivors. The effect on depression, however, appeared less robust. One possible reason for this could be that the baseline scores were within the range of "mild depression," 36 and could thus indicate a floor effect.
One solution for including the patients most likely to benefit could be a more comprehensive screening procedure or a higher cut-off when screening patients.
While the post-intervention effect sizes for anxiety and depression found in our study (0.45 and 0.42) are within the same range as those reported in a meta-analysis of face-to-face group MBIs with cancer patients (0.37 and 0.44) 11, 18 and the effect found on mood disturbance in the feasibility study of online mindfulness-based cancer recovery (0.44), 17 cut-offs were applied in the previous studies, ie, HADS scores greater than or equal to 11 18 and distress thermometer scores greater than or equal to 4, 17 the present study used a lower cut-off, which could have introduced floor effects. In addition, the previous studies recruited patients through self-referral, yielding higher inclusion rates, ie, 56% 18 and 48%. 17 In the present study, only 39% of eligible patients were enrolled, and one third of those who gave consent to be contacted about the study declined after receiving oral information.
Thus, while many cancer survivors experience distress, all eligible patients may not find iMBCT equally attractive, and providing iMBCT as a routine offer based on a screening procedure may have included less motivated participants in the present study compared with studies with self-referral.
Older age emerged a significant predictor of study attrition, i.e., failing to return questionnaires. Age was, however, not associated with intervention drop-out, i.e., discontinuation of the iMBCT program. This result may be important to consider when offering internet-delivered therapy to an ageing population in a study setting. Self-reported reasons for dropping out of the intervention were lack of motivation and insufficient IT skills, and it has previously been found that cancer patients prefer face-to-face therapy when asked about preferences. 37 With respect to intervention adherence, the number of modules completed did not appear to be associated with the magnitude of effects 
Study limitations
The present study has a number of limitations that should be noted.
First, although the sample size was relatively large, we only nearly achieved the intended inclusion rate. Second, the control condition was a wait-list CAU condition, which enables the initial evaluation of the relevance of the intervention in the clinical setting. This may be insufficient when assessing the efficacy of the intervention, where an active control condition could have been relevant. Likewise, evaluating non-inferiority by directly comparing iMBCT with face-to-face MBCT, as discussed in Compen et al, 18 is highly relevant. We had originally planned to include a third face-to-face MBCT arm, but were forced to abandon this approach because of insufficient resources and too few patients available for the study. Third, the distribution of breast and prostate cancer participants in our study sample was uneven. Between-cancer type differences in follow-up procedures provided fewer eligible prostate cancer survivors. The follow-up period for breast cancer is 5 years compared with only 1 year for prostate cancer. Because of the nature of their disease, the two patient groups also differ on several parameters, including gender, age, late effects, and prescription medicine used. While it appears that both breast and prostate cancer survivors may benefit from iMBCT (Table   S4 ), our study is likely underpowered to discern to which degree such cancer type-related differences influence acceptance and efficacy of iMBCT. Finally, a high attrition rate was observed in the intervention group, especially at the beginning of intervention, which could indicate insufficient recruitment and information procedures. It could be that this type of intervention does not fully meet the needs, expectations, and skills of the target population. Participants completed online questionnaires covering these aspects prior to randomization, but additional in-depth assessment of motivation and computer literacy prior to intervention start could have been relevant.
Clinical implications
iMBCT appears to be a feasible and flexible intervention for cancer survivors experiencing distress, with promising effects on anxiety and possibly depressive symptoms. Participants attend the programme from their homes, which may be attractive to groups of patients who do not typically seek psychological treatment. We find, in particular, the completion rate and effect among older men treated for prostate cancer encouraging.
| CONCLUSION
Taken together, iMBCT showed positive effects for anxiety and depression immediately after treatment and for anxiety and well-being at the 6-month follow-up. Despite our intention of maximizing access to treatment by reducing practical barriers for attending face-to-face treatment, a substantial percentage of distressed cancer survivors were not interested in an iMBCT intervention when offered as a part of routine follow-up care.
